Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.

PURPOSE To prospectively and directly compare the capability of whole-body diffusion-weighted (DW) imaging, whole-body magnetic resonance (MR) imaging with and that without DW imaging, and integrated fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for M-stage assessment in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS The institutional review board approved this study; informed consent was obtained from patients. A total of 203 NSCLC patients (109 men, 94 women; mean age, 72 years) prospectively underwent whole-body DW imaging, whole-body MR imaging, and FDG PET/CT. Final diagnosis of the M-stage in each patient was determined on the basis of results of all radiologic and follow-up examinations. Two chest radiologists and two nuclear medicine physicians independently assessed all examination results and used a five-point visual scoring system to evaluate the probability of metastases. Final diagnosis based on each of the methods was made by consensus of two readers. Receiver operating characteristic (ROC) analysis was used to compare the capability for M-stage assessment among whole-body DW imaging, whole-body MR imaging with and that without DW imaging, and PET/CT on a per-patient basis. Sensitivity, specificity, and accuracy were compared with the McNemar test. RESULTS Area under ROC curve (A(z)) values of whole-body MR imaging with DW imaging (A(z) = 0.87, P = .04) and integrated FDG PET/CT (A(z) = 0.89, P = .02) were significantly larger than that of whole-body DW imaging (A(z) = 0.79). Specificity and accuracy of whole-body MR imaging with (specificity, P = .02; accuracy, P < .01) and that without DW imaging (specificity, P = .02; accuracy, P = .01) and integrated FDG PET/CT (specificity, P < .01; accuracy, P < .01) were significantly higher than those of whole-body DW imaging. CONCLUSION Whole-body MR imaging with DW imaging can be used for M-stage assessment in NSCLC patients with accuracy as good as that of PET/CT.

[1]  I. Narabayashi,et al.  2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience , 2007, Annals of nuclear medicine.

[2]  J. Debatin,et al.  Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: feasibility study. , 2001, Radiology.

[3]  R C Young,et al.  Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.

[4]  Michael T. Halpern,et al.  EVALUATION OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF ANEMIA AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS , 2005 .

[5]  Susumu Mori,et al.  Diffusion-tensor MR imaging and fiber tractography: a new method of describing aberrant fiber connections in developmental CNS anomalies. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.

[6]  N. deSouza,et al.  Diffusion-weighted magnetic resonance imaging and its application to cancer , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.

[7]  K. Mori,et al.  Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. , 1999, Chest.

[8]  Werner Hacke,et al.  Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke: Present Status , 2003, Stroke.

[9]  H. Svanholm,et al.  Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic , 1989, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  A. A. Abdel Razek,et al.  Role of diffusion-weighted MR imaging in cervical lymphadenopathy , 2006, European Radiology.

[11]  M. Matoba,et al.  Lung carcinoma: diffusion-weighted mr imaging--preliminary evaluation with apparent diffusion coefficient. , 2007, Radiology.

[12]  R. Kerbel,et al.  Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. , 1995, Anti-cancer drugs.

[13]  C. Claussen,et al.  Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping—Initial Clinical Experiences in Comparison to PET-CT , 2007, Investigative radiology.

[14]  J. Debatin,et al.  Whole-body MR imaging: evaluation of patients for metastases. , 2004, Radiology.

[15]  L. Tanoue,et al.  The noninvasive staging of non-small cell lung cancer: the guidelines. , 2003, Chest.

[16]  D. Figarella-Branger,et al.  Fetal brain injury. , 2004, Journal of neuroradiology. Journal de neuroradiologie.

[17]  R. Walker,et al.  Turbo STIR magnetic resonance imaging as a whole‐body screening tool for metastases in patients with breast carcinoma: Preliminary clinical experience , 2000, Journal of magnetic resonance imaging : JMRI.

[18]  T. Turkington,et al.  Clinical applications of PET in oncology. , 2004, Radiology.

[19]  T. Takahara,et al.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.

[20]  Y. Ohno,et al.  Whole‐body MR imaging vs. FDG‐PET: Comparison of accuracy of M‐stage diagnosis for lung cancer patients , 2007, Journal of magnetic resonance imaging : JMRI.

[21]  V. Narra,et al.  Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. , 2002, AJR. American journal of roentgenology.

[22]  J. Deslauriers.  Current surgical treatment of nonsmall cell lung cancer 2001 , 2002, European Respiratory Journal.

[23]  R. Govindan,et al.  Recent advances and future perspectives in the management of lung cancer. , 2005, Current problems in surgery.

[24]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[25]  Heiko Schöder,et al.  Deep-Inspiration Breath-Hold PET/CT: Clinical Findings with a New Technique for Detection and Characterization of Thoracic Lesions , 2007, Journal of Nuclear Medicine.

[26]  R. Coleman,et al.  Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. , 2003, Radiology.

[27]  Alfred A Bartolucci,et al.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.

[28]  Adolf Pfefferbaum,et al.  Using Magnetic Resonance Imaging and Diffusion Tensor Imaging to Assess Brain Damage in Alcoholics , 2003, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[29]  O. Schober,et al.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.

[30]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[31]  N. Obuchowski,et al.  Adrenal mass evaluation in patients with lung carcinoma: a cost-effectiveness analysis. , 2000, AJR. American journal of roentgenology.

[32]  Abass Alavi,et al.  Whole-body FDG-PET imaging in the management of patients with cancer. , 2002, Seminars in nuclear medicine.

[33]  A M Aisen,et al.  Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. , 1995, Radiology.

[34]  S. Nawano,et al.  Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. , 2006, Radiology.

[35]  U. Tateishi,et al.  Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. , 2007, Radiology.

[36]  E. O. Bregman,et al.  The Present Status. , 1926 .

[37]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[38]  H. Gerth,et al.  Significant Benefit of Multimodal Imaging: PET/CT Compared with PET Alone in Staging and Follow-up of Patients with Ewing Tumors , 2007, Journal of Nuclear Medicine.

[39]  M. J. Fusselman,et al.  Brain metastases from non-central nervous system tumors: evaluation with PET. , 1993, Radiology.

[40]  Michael E Phelps,et al.  Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. , 2005, Chest.

[41]  M. Salvatore,et al.  18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma , 2008, Journal of Nuclear Medicine.

[42]  M. Melamed,et al.  Impact of early detection on the clinical course of lung cancer. , 1987, The Surgical clinics of North America.

[43]  S. Swensen,et al.  Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection--pilot study. , 1999, Radiology.

[44]  V. Muse,et al.  Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  L. Liotta,et al.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.